Hangzhou Tigermed Medical Technology Co., Ltd. 2025 Annual Internal Control Self-Evaluation Report Hangzhou Tigermed Medical Technology Co., Ltd. 2025 Annual Internal Control Self-Evaluation Report (As of December 31, 2025) To the Shareholders of Hangzhou Tigermed Medical Technology Co., Ltd.: In accordance with the "Basic Norms for Enterprise Internal Control" and its supporting guidelines, as well as other internal control regulatory requirements (hereinafter referred to as the "Enterprise Internal Control Norms"), and combined with Hangzhou Tigermed Medical Technology Co., Ltd.'s (hereinafter referred to as the "Company") internal control system and evaluation methods, based on daily supervision and special supervision of internal controls, we have evaluated the effectiveness of the Company's internal controls as of December 31, 2025 (the "Internal Control Evaluation Report Base Date").
I. Important Statement The Company's Board of Directors, Directors, and Senior Management guarantee that the content of this report is free from any false records, misleading statements, or material omissions, and they bear individual and joint legal responsibility for the authenticity, accuracy, and completeness of the report's content. In accordance with the requirements of the Enterprise Internal Control Norms, the establishment, improvement, and effective implementation of internal controls, the evaluation of their effectiveness, and the truthful disclosure of the internal control evaluation report are the responsibilities of the Company's Board of Directors. The management is responsible for organizing and leading the daily operation of the Company's internal controls. The objectives of the Company's internal controls are to reasonably ensure that business operations are legal and compliant, assets are secure, financial reports and related information are true and complete, operating efficiency and effectiveness are improved, and development strategies are achieved. Due to the inherent limitations of internal control, it can only provide reasonable assurance for achieving these objectives. Furthermore, due to changes in circumstances, internal controls may become inappropriate, or the degree of compliance with control policies and procedures may decrease. Predicting the future effectiveness of internal controls based on the results of the internal control evaluation carries certain risks.
II. Conclusion of Internal Control Evaluation The Board of Directors believes that the Company has, in all material respects, maintained effective internal controls over financial reporting in accordance with the requirements of the Enterprise Internal Control Norms and relevant regulations. As of the Internal Control Evaluation Report Base Date, there were no material weaknesses in internal controls over financial reporting. The Board of Directors believes that as of the Internal Control Evaluation Report Base Date, there were no material weaknesses in internal controls other than financial reporting. No factors have occurred between the Internal Control Evaluation Report Base Date and the issuance date of the Internal Control Evaluation Report that affect the conclusion of the internal control effectiveness evaluation.
III. Scope and Basis of Internal Control Evaluation (I) Scope of Internal Control Evaluation The Company determines the scope of evaluation, key entities, matters, and high-risk areas based on a risk-oriented approach. The key entities included in the evaluation scope are Hangzhou Tigermed Medical Technology Co., Ltd. and its wholly-owned and controlling subsidiaries. The key matters included in the evaluation scope are: corporate governance, development strategy, human resources, corporate culture, and social responsibility. Key high-risk areas focused on include: procurement control, sales control, fixed asset control, cost and expense control, engineering project control,